[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-351649-105":59,"doc-detail-351649-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","akr1c3-pkm2-oxidative-phosphorylation-axis-drives-prostate-cancer-radioresistance-via-ube2t-upregulation","AKR1C3–PKM2–oxidative phosphorylation axis drives prostate cancer radioresistance via UBE2T upregulation","","Radioresistance remains a major cause of prostate cancer treatment failure and post-radiotherapy progression, yet reliable targets to enhance radiotherapy sensitivity are limited. AKR1C3 was identified as a key driver of radioresistance and malignant progression using integrated bioinformatic analysis of RNA-seq data from TCGA and GEO. AKR1C3 promoted radioresistance in both AR-positive and AR-negative prostate cancer via in vivo and in vitro validation. Mechanistically, AKR1C3 binds to PKM2, accelerates its degradation, suppresses glycolysis and increases oxidative phosphorylation, elevating ROS that triggers NRF2 nuclear translocation and activates UBE2T transcription. Enhanced DNA repair underlies stronger radiotherapy resistance in AKR1C3-high cells, supporting AKR1C3 as a therapeutic target.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/akr1c3-pkm2-oxidative-phosphorylation-axis-drives-prostate-cancer-radioresistance-via-ube2t-upregulation/351649/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/akr1c3-pkm2-oxidative-phosphorylation-axis-drives-prostate-cancer-radioresistance-via-ube2t-upregulation/351649.png","ImageObject",300,407,{"name":92,"@type":93},"Đào","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-30","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why is radioresistance important in prostate cancer treatment outcomes?","Question",{"text":112,"@type":113},"Radioresistance is a primary cause of treatment failure and post-radiotherapy progression in prostate cancer, limiting durable control after radiotherapy.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How did the study identify AKR1C3 as a key factor in radioresistance?",{"text":117,"@type":113},"Through integrated bioinformatic analysis of public RNA-seq datasets from TCGA and GEO, AKR1C3 overexpression was found to correlate with both radioresistance and disease progression, followed by experimental validation.",{"name":119,"@type":110,"acceptedAnswer":120},"What mechanism links AKR1C3 to enhanced radiotherapy resistance?",{"text":121,"@type":113},"AKR1C3 binds PKM2 and promotes its degradation, suppressing glycolysis while increasing oxidative phosphorylation; elevated ROS then drives NRF2 nuclear translocation to activate UBE2T transcription, strengthening DNA repair and thus radiotherapy resistance.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},351649,1790167126,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":36,"preview_page_count":19,"preview_urls":145},1374402968488,"https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","[www.nature.com/cddis](www.nature.com/cddis)  \nARTICLE OPEN   \nAKR1C3–PKM2–oxidative phosphorylation axis drives prostate cancer radioresistance via UBE2T upregulation  \nJinyu Zhang1, Jiongzheng Li1, Yufei Yan1, Binghuan Wang 1, Ruojia Wang 1, Xiaoli Cui2 ✉, Yang Zhan3, Zuowen Liang 1 and Jing Li 1 ✉  \n© The Author(s) 2026  \n|  |  |  |\n| --- | --- | --- |\n|  | Radioresistance is one of the primary causes of prostate cancer treatment failure and post-radiotherapy progression. However, there is currently a lack of effective targets to increase radiotherapy sensitivity and inhibit malignant progression. We identiﬁed AKR1C3 as a potential key target associated with radioresistance and malignant progression through integrated bioinformatic analysis of RNA sequencing (RNA-seq) data from prostate cancer clinical samples in The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) databases. The promotion of radioresistance by AKR1C3 in both AR-positive and AR-negative prostate cancer cells was further validated through in vivo and in vitro experiments. Mechanistic studies revealed that AKR1C3 can bind to PKM2 and accelerate its degradation, thereby inhibiting glycolytic ﬂux and enhancing oxidative phosphorylation (OXPHOS) . Increased OXPHOS boosts ROS production, which further promotes NRF2 nuclear translocation, activating the transcription of DNA repair protein UBE2T. This enhanced DNA damage repair ability enables prostate cancer cells with high AKR1C3 expression to exhibit greater resistance to radiotherapy. In summary, this study reveals the molecular mechanism by which AKR1C3 is involved in metabolic reprogramming to promote radioresistance in prostate cancer through PKM2/UBE2T. These ﬁndings indicate that targeting AKR1C3 has potential for overcoming radioresistance, providing novel insight into the clinical treatment of prostate |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n| cancer. |  |  |\n|  | Cell Death and Disease (2026)17:433; [https://doi.org/10.1038/s41419-026-08666-5](https://doi.org/10.1038/s41419-026-08666-5) |  |\n|  |  |  |\n\nINTRODUCTION  \nProstate cancer (PCa) is a prevalent malignancy in men and its development is tightly linked to androgens [1] . According to cancer statistics from 2025, prostate cancer accounts for approximately 30% of all newly diagnosed cancer cases among men in the United States, representing the most commonly diagnosed malignancy in men. Additionally, prostate cancer contributes to 11% of cancer-related deaths, ranking as the second leading cause of cancer mortality among men [2] . Clinically, prostate cancer is classiﬁed into stages I to IV, each with well-established standard therapeutic protocols. Radiotherapy (RT) is an effective treatment option for prostate cancer at all stages, particularly in patients with localised disease [3] . However, some patients develop radioresistance following standalone or combined radiotherapy [4] . If early RT and/or androgen deprivation therapy (ADT) fails, the disease may progress to castrationresistant prostate cancer (CRPC), which is incurable [5] . The mechanisms driving radioresistance in PCa remain incompletely deﬁned and effective clinical targets to prevent or mitigate radioresistance and delay tumour progression are lacking. Thus, elucidating the biological basis of radioresistance and devising innovative therapeutic strategies holds profound clinical implications for disease management.  \nRadiotherapy induces DNA damage in tumour cells by ionising radiation (IR), triggering the DNA damage response (DDR) to repair  \ndamage and sustain cell survival [6]. In radioresistant cells, DDR proteins such as PRKDC, RAD51 and UBE2T are frequently overexpressed, thereby increasing the ability of cells to repair DNA [7–9]. Given that therapeutic radiation causes damage within minutes, de novo protein synthesis cannot account for this protective response. We hypothesize t","cbCaitqK3DaR9LPO","https://ap.wps.com/l/cbCaitqK3DaR9LPO","pdf",4180214,16,"English","# Introduction\n## Prostate cancer and radioresistance\n## DNA damage response and therapeutic radiation\n## Hypothesis and identification of AKR1C3\n## AKR1C3 functions in malignant progression","[{\"question\":\"Why is radioresistance important in prostate cancer treatment outcomes?\",\"answer\":\"Radioresistance is a primary cause of treatment failure and post-radiotherapy progression in prostate cancer, limiting durable control after radiotherapy.\"},{\"question\":\"How did the study identify AKR1C3 as a key factor in radioresistance?\",\"answer\":\"Through integrated bioinformatic analysis of public RNA-seq datasets from TCGA and GEO, AKR1C3 overexpression was found to correlate with both radioresistance and disease progression, followed by experimental validation.\"},{\"question\":\"What mechanism links AKR1C3 to enhanced radiotherapy resistance?\",\"answer\":\"AKR1C3 binds PKM2 and promotes its degradation, suppressing glycolysis while increasing oxidative phosphorylation; elevated ROS then drives NRF2 nuclear translocation to activate UBE2T transcription, strengthening DNA repair and thus radiotherapy resistance.\"}]","AKR1C3–PKM2–oxidative phosphorylation axis drives prostate cancer radioresistance via UBE2T upregulation | PDF",1790095109,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/918476bc3c0df7e9944299b8f0e81c65.webp",983,1305,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/90290c91581c7bdd6d2558b33c2ec810.webp",982,1304,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a4b1dc1955b1bbab258bdad410119764.webp",981,1303,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0b57329f5455e5240bc961185825a037.webp",980,1301]